Trade Moderna Inc ^MRNA

CureVac sues Moderna for patent infringement over COVID-19 vaccines

Assessing Moderna (MRNA) Valuation After European Approval Of First Flu Plus COVID Combination Vaccine

Moderna (MRNA) Expected to Announce Earnings on Friday

Moderna News Ties Combo Vaccine Approval To Broader mRNA Prospects

Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran

Bird flu vaccine trial begins to fight 'real possibility' of virus threat for humans

First bird flu mRNA vaccine enters late-stage trial

Biotech Stocks To Consider - April 19th - Stock Observer

Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine

Post-vaccine inflammation tracking: validation of a novel individualized digital inflammatory biomarker relative to serum biomarkers

Moderna initiates Phase 3 study of mRNA Pandemic influenza vaccine | Markets Insider

Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth

Promising Biotech Stocks To Follow Today - April 21st - Markets Daily

Moderna (MRNA) Secures EU Approval for mRNA Combination Vaccine

Moderna (MRNA) Secures EU Approval for mCOMBRIAX Vaccine

Moderna wins EU approval for combined flu, COVID shot for older adults

Promising Biotech Stocks To Consider - April 20th - Markets Daily

Moderna's Quarterly Earnings Preview: What You Need to Know

Is It Too Late To Consider Moderna (MRNA) After A 114% One Year Surge?

Moderna's mRNA Melanoma Data And Fast Track Status Shape Oncology Story

Moderna (MRNA) Is Up 5.4% After Fast Track Win For Melanoma mRNA Therapy Combo - Has The Bull Case Changed?

Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study

Sanofi says COVID-19 vaccine showed better tolerability than Moderna's | Markets Insider

Moderna (MRNA) Advances Cancer Therapy Research with Promising Data

What Moderna (MRNA)'s Expedited Flu Vaccine Review And Institutional Support Means For Shareholders

Top Biotech Stocks To Watch Today - April 16th - Stock Observer

Assessing Moderna (MRNA) Valuation After Recent Share Price Momentum And Mixed Long Term Returns

Chandrakant Lahariya | Flu-COVID Combo Vaccines: An Idea Whose Time Has Not Yet Arrived

Baillie Gifford & Co. Sells 1,266,152 Shares of Moderna, Inc. $MRNA

Head-To-Head Analysis: Tharimmune (NASDAQ:THAR) vs. Moderna (NASDAQ:MRNA) - Daily Political

Biotech Stocks To Research - April 11th - Markets Daily

CDC Delays Reporting Of COVID-19 Vaccine Benefits-Here's What To Know - Yahoo News Canada

Moderna Target of Unusually High Options Trading (NASDAQ:MRNA)

New Flu and RSV mRNA Data Might Change The Case For Investing In Moderna (MRNA)

Promising Biotech Stocks To Follow Today - April 10th - Stock Observer

Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC

Is Moderna (MRNA) Priced Too High After A 66% Year To Date Rally?

3 Mid-Cap Stocks We're Skeptical Of

Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy? - AOL

Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension

Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna Flu And RSV Data Highlight Progress Toward Repeat Vaccination Business

Biotech Stocks To Keep An Eye On - April 8th - Daily Political

Analysts Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $32.33 - Stock Observer

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, I

Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes

Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA) | Markets Insider

Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump

This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.

Biotech Stocks To Watch Now - April 3rd - Daily Political

Why Moderna (MRNA) Is Down 6.6% After Its 'Moderna 2.0' Cancer-Vaccine Pivot - And What's Next - Simply Wall St News

Moderna (NASDAQ:MRNA) Price Target Raised to $48.00 at Barclays

Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of "Reduce" by Brokerages

Exclusive-Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - Yahoo News UK

Biotech Stocks To Consider - April 1st - Markets Daily

Moderna (MRNA) Valuation Check As Moderna 2.0 Oncology Pivot And Legal Settlement Shift Expectations

Promising Biotech Stocks To Watch Now - March 31st - Daily Political

3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next

A Look Back at Biotechnology Stocks' Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack

MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance

Moderna's Diverging Flu Vaccine Rulings May Shift mRNA Growth Story

Biotech Stocks To Keep An Eye On - March 28th - Stock Observer

Stock Traders Purchase High Volume of Call Options on Moderna (NASDAQ:MRNA) - Daily Political

Moderna Faces EMA Approval And FDA Pushback As Valuation Risks Mount

Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA)

Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know

Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - Stock Observer

2 Healthcare Stocks That Could Soar Over the Next 5 Years